98 related articles for article (PubMed ID: 10887640)
1. CD26 in T-cell lymphomas: a potential clinical role?
Verstovsek S; Cabanillas F; Dang NH
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):17-23. PubMed ID: 10887640
[TBL] [Abstract][Full Text] [Related]
2. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Dang NH; Hagemeister FB; Duvic M; Romaguera JE; Younes A; Jones D; Samuels B; Fayad LE; Pro B; Samaniego F; Sarris A; Goy A; McLaughlin P; Tong AT; Walker PL; Tiongson LP; Smith TL; Huh YO; Morimoto C; Rodriguez MA
Oncol Rep; 2003; 10(5):1513-8. PubMed ID: 12883733
[TBL] [Abstract][Full Text] [Related]
3. CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).
Sato K; Dang NH
Int J Oncol; 2003 Mar; 22(3):481-97. PubMed ID: 12579300
[TBL] [Abstract][Full Text] [Related]
4. CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.
Aldinucci D; Poletto D; Lorenzon D; Nanni P; Degan M; Olivo K; Rapanà B; Pinto A; Gattei V
Clin Cancer Res; 2004 Jan; 10(2):508-20. PubMed ID: 14760072
[TBL] [Abstract][Full Text] [Related]
5. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias.
Carbone A; Gloghini A; Zagonel V; Aldinucci D; Gattei V; Degan M; Improta S; Sorio R; Monfardini S; Pinto A
Blood; 1995 Dec; 86(12):4617-26. PubMed ID: 8541553
[TBL] [Abstract][Full Text] [Related]
6. Pentostatin treatment of cutaneous T-cell lymphoma.
Dearden C; Matutes E; Catovsky D
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):37-40. PubMed ID: 10887643
[TBL] [Abstract][Full Text] [Related]
7. Pentostatin (Nipent) in T-cell lymphomas.
Kurzrock R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):64-6. PubMed ID: 10877055
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Tsimberidou AM; Giles F; Duvic M; Fayad L; Kurzrock R
Cancer; 2004 Jan; 100(2):342-9. PubMed ID: 14716770
[TBL] [Abstract][Full Text] [Related]
9. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
10. Phase II trials of pentostatin (Nipent) in hairy cell leukemia.
Kraut EH
Semin Oncol; 2000 Apr; 27(2 Suppl 5):27-31. PubMed ID: 10877048
[TBL] [Abstract][Full Text] [Related]
11. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
Foss FM
Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with purine nucleoside analogs.
Foss FM
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):31-5. PubMed ID: 10887642
[TBL] [Abstract][Full Text] [Related]
13. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations.
Kurzrock R; Pilat S; Duvic M
J Clin Oncol; 1999 Oct; 17(10):3117-21. PubMed ID: 10506607
[TBL] [Abstract][Full Text] [Related]
14. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Dearden CE; Matutes E; Catovsky D
Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
[TBL] [Abstract][Full Text] [Related]
15. Purine nucleoside analogs in indolent non-Hodgkin's lymphoma.
Cabanillas F
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):13-5. PubMed ID: 10887639
[TBL] [Abstract][Full Text] [Related]
16. Pentostatin and rituximab in the treatment of patients with B-cell malignancies.
Drapkin R
Oncology (Williston Park); 2000 Jun; 14(6 Suppl 2):25-9. PubMed ID: 10887641
[TBL] [Abstract][Full Text] [Related]
17. Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.
Yamochi T; Yamochi T; Aytac U; Sato T; Sato K; Ohnuma K; McKee KS; Morimoto C; Dang NH
Cancer Res; 2005 Mar; 65(5):1973-83. PubMed ID: 15753397
[TBL] [Abstract][Full Text] [Related]
18. Pentostatin and purine analogs for indolent lymphoid malignancies.
Ho AD; Hensel M
Future Oncol; 2006 Apr; 2(2):169-83. PubMed ID: 16563086
[TBL] [Abstract][Full Text] [Related]
19. Classification of cell lineage and anatomical site, and prognosis of extranodal T-cell lymphoma -- natural killer cell, cytotoxic T lymphocyte, and non-NK/CTL types.
Ohshima K; Liu Q; Koga T; Suzumiya J; Kikuchi M
Virchows Arch; 2002 Apr; 440(4):425-35. PubMed ID: 11956825
[TBL] [Abstract][Full Text] [Related]
20. CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL.
Cro L; Morabito F; Zucal N; Fabris S; Lionetti M; Cutrona G; Rossi F; Gentile M; Ferrario A; Ferrarini M; Molica S; Neri A; Baldini L
Hematol Oncol; 2009 Sep; 27(3):140-7. PubMed ID: 19247978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
